Skip to main content
Top

Cancer Microenvironment

Issue 1/2012

Content (9 Articles)

Original Paper

The Inflammatory Tumor Microenvironment, Epithelial Mesenchymal Transition and Lung Carcinogenesis

Eileen L. Heinrich, Tonya C. Walser, Kostyantyn Krysan, Elvira L. Liclican, Jeanette L. Grant, Nicole L. Rodriguez, Steven M. Dubinett

Original Paper

Partial Mesenchymal to Epithelial Reverting Transition in Breast and Prostate Cancer Metastases

Yvonne Chao, Qian Wu, Marie Acquafondata, Rajiv Dhir, Alan Wells

Review Paper

Epithelial-Mesenchymal Transition Induced by Senescent Fibroblasts

Remi-Martin Laberge, Pierre Awad, Judith Campisi, Pierre-Yves Desprez

Original Paper

Adipocytes Promote B16BL6 Melanoma Cell Invasion and the Epithelial-to-Mesenchymal Transition

Kyoko Kushiro, Randy A. Chu, Akanksha Verma, Nomelí P. Núñez

Original Paper

Contribution of Fibroblast and Mast Cell (Afferent) and Tumor (Efferent) IL-6 Effects within the Tumor Microenvironment

Honor J. Hugo, Stephanie Lebret, Eva Tomaskovic-Crook, Nuzhat Ahmed, Tony Blick, Donald F. Newgreen, Erik W. Thompson, M. Leigh Ackland

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine